A Brief History of Drug Coated Balloon (DCB) Development Yuan Jiansong, Department of Cardiovascular Medicine, Fu Wai Hospital, Beijing
Yuan Jiansong
In 2004
Scheller was the first to report that DCB prevented in-stent restenosis in porcine coronary arteries
Paclitaxel-coated balloons significantly reduce the incidence of ISR compared with conventional balloons
First human clinical study of DCB for ISR (PACCOCATH-ISR) initiated
2007
PACCOCATH-ISR results published
Paclitaxel-coated balloons significantly reduce: late lumen loss (LLL), target lesion revascularization (TLR), and major cardiovascular events (MACE) compared to conventional balloons
In 2009
Drug-coated balloons received CE mark and began clinical use in Europe
2010
ESC/EACTS guidelines for myocardial revascularization: The use of drug-coated balloons should be considered for bare stent (BMS) restenosis (IIa B)
2014
ESC/EACTS Guidelines for myocardial revascularization: The use of drug balloons should be considered for restenosis (bare and drug stents) (I A)